Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...

AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, widening rival Bristol Myers Squibb's lead in the market ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Why I Think BMY Stock Is Undervalued? Bristol Myers Squibb was in a strong position in Q2 FY2024, reporting sales of ~$12.20 billion (+9% YoY), which was about $679 million above consensus ...

Okay. So, in the interest of staying on time here, really pleased to have Bristol Myers Squibb joining us. To my immediate right is Samit Hirawat. He is the Chief Medical Officer and Head of ...

AbbVie said it was disappointed with the results of its emraclidine trial for treating schizophrenia Bristol Myers Squibb Co. shares surged on Monday after rival AbbVie Inc. reported disappointing ...